Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.
Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries
Data from latest research presented at the ESMO Virtual Congress 2020
For enquiries please contact us on media@esmo.org
The ALK tyrosine kinase inhibitor lorlatinib significantly improved progression-free survival compared with crizotinib
Mixed results from IMpassion 130 and IMpassion 131 also draw attention to chemotherapy backbone selection
In the Phase III trial, sacituzumab govitecan significantly improved progression-free survival and overall survival over standard chemotherapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
